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Abstract
Depression affects 20–30% of people living with HIV/AIDS (PLWHA) in the US and predicts
greater sexual risk behaviors, lower antiretroviral (ARV) medication adherence, and worse clinical
outcomes. Yet little experimental evidence addresses the critical clinical question of whether
depression treatment improves ARV adherence and clinical outcomes in PLWHA with depression.
The Strategies to Link Antidepressant and Antiretroviral Management at Duke, UAB, and UNC
(SLAM DUNC) Study is a randomized clinical effectiveness trial funded by the National Institute
for Mental Health. The objective of SLAM DUNC is to test whether a depression treatment
program integrated into routine HIV clinical care affects ARV adherence. PLWHA with
depression (n=390) are randomized to enhanced usual care or a depression treatment model called
Measurement-Based Care (MBC). MBC deploys a clinically supervised Depression Care Manager
(DCM) to provide evidence-based antidepressant treatment recommendations to a non-psychiatric
prescribing provider, guided by systematic and ongoing measures of depressive symptoms and
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side effects. MBC has limited time requirements and the DCM role can be effectively filled by a
range of personnel given appropriate training and supervision, enhancing replicability. In SLAM
DUNC, MBC is integrated into HIV care to support HIV providers in antidepressant prescription
and management. The primary endpoint is ARV adherence measured by unannounced telephone-
based pill counts at 6 months with follow-up to 12 months and secondary endpoints including viral
load, health care utilization, and depressive severity. Important outcomes of this study will be
evidence of the effectiveness of MBC in treating depression in PLWHA and improving HIV-
related outcomes.
Keywords
HIV; depression; adherence; Measurement-Based Care; randomized controlled trial; effectiveness
trial
Introduction
Depression is a serious comorbidity in the clinical management of HIV infection, affecting
20–30% of people living with HIV/AIDS (PLWHA) in the United States. In HIV-infected
patients, depression predicts greater sexual risk behaviors, lower antiretroviral (ARV)
medication adherence, and worse clinical outcomes. Yet little evidence, especially
experimental evidence, addresses the critical clinical question of whether depression
treatment will improve ARV adherence and clinical outcomes in HIV-infected patients with
depression. In this paper we present the rationale and design of the Strategies to Link
Antidepressant and Antiretroviral Management at Duke, UAB, and UNC (SLAM DUNC)
Study, a NIMH-funded randomized clinical effectiveness trial that tests whether a
depression treatment program integrated into routine HIV clinical care affects ARV
adherence.
Background and Rationale (Summary in Box 1)
Box 1
Background and Rationale: Major points
• Depression is prevalent in HIV patients, and frequently goes clinically
unrecognized and untreated.
• Depression is associated with worse ARV adherence and clinical outcomes.
• Standard depression treatments work well for HIV patients.
• In observational studies, depression treatment is associated with better ARV
adherence.
• Depression treatment has shown promise in improving medical outcomes in
patients with diabetes and hypertension.
• Measurement-Based Care is a feasible model for integrating vigorous
antidepressant prescription support into non-psychiatric clinical settings.
Prevalence of depression in HIV patients
Since the emergence of AIDS in the early 1980’s, psychiatric needs of PLWHA have been
recognized as unique and significant.1–3 The HIV/AIDS Costs and Services Utilization
Study (HCSUS), a U.S. survey of a national probability sample of PLWHA in care, found
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that nearly half (48%) of participants had a probable diagnosis of a mental disorder and 35%
screened positive for depression.4 The most common psychiatric diagnoses among PLWHA
are mood and anxiety disorders, particularly major depression and other depressive
disorders.5–8 The major mood and anxiety disorders are five to ten times more prevalent in
PLWHA than in the general U.S. population.9 A meta-analysis of studies between 1988 and
1998 found that major depressive disorder was twice as frequent in PLWHA relative to
comparable HIV-uninfected persons.10 More recent evidence continues to bear out this
relationship.11–18 Despite its high prevalence, depression is under-recognized by primary
HIV medical providers with subsequent under-utilization of psychiatric treatment.19
Association of depression with ARV adherence and HIV clinical outcomes
In PLWHA, depression has been consistently associated with deleterious HIV-related
behaviors, particularly poor antiretroviral medication adherence.20,21 Indeed, a recent meta-
analysis of 95 studies encompassing 35,029 participants reported a pooled correlation
coefficient across studies for the relationship of depression with medication adherence of r =
0·19 (95% CI: 0·14–0·25), a relationship which was consistent between cross-sectional and
longitudinal studies and low-resource and high-resource settings.22 Adherence is a critical
consideration in HIV care where complex ARV regimens play a central role in suppressing
viral replication and protecting the immune system.23 Depression has also been associated
with a wide range of unfavorable health outcomes including poorer physical health,24
decreased quality of life,25 lower likelihood of receiving ARV medications,26 poor response
to ARV,27 and increased AIDS-related mortality,28 as recently summarized in a
comprehensive review.29 In the HIV Epidemiology Research Study (HERS), a multisite
longitudinal cohort study of HIV-infected women, participants who were chronically
depressed over the course of the study progressed to death from AIDS twice as quickly as
participants with intermittent or no symptoms of depression.28
Efficacy of standard depression interventions for HIV patients
Standard pharmacological and psychotherapeutic interventions are efficacious in treating
depression in PLWHA. Two meta-analyses of randomized controlled trials (RCTs) of
antidepressant-based30 and group therapy-based31 depression treatment in PLWHA
estimated pooled effect sizes of 0.57 (95% CI 0.28–0.85) and 0.38 (0.23–0.53), respectively.
Of note, none of the 15 RCTs reviewed in these two meta-analyses considered ARV
medication adherence or HIV clinical indicators as secondary outcomes.
Association of depression treatment with improved ARV adherence
The available evidence addressing whether depression treatment improves adherence is
limited but promising. A few trials of psychotherapy-based depression treatment strategies
in small samples have shown improvements in ARV adherence.32–34 For example, Weber et
al. reported 70% of intervention arm participants achieving at least 95% ARV adherence
compared to 50% of treatment-as-usual participants, and Safren reported a Cohen’s effect
size of 1.0 fpr the difference in continuously measured pre- and post-treatment ARV
adherence comparing the CBT arm to the waitlist control arm. Observational evidence has
identified an association between antidepressant treatment and improved adherence. Three
recent observational studies each analyzed retrospective records and reported higher ARV
refill adherence associated with antidepressant prescription and with antidepressant refill
adherence.35–37 For example, among HIV patients with depression, Walkup reported an
odds ratio for current-month ARV prescription adherence of 1.28 comparing those with
past-month antidepressant prescription to those without, and Yun reported an odds ratio for
achieving at least 95% ARV refill adherence of 2.45 comparing those with antidepressant
refill adherence above the median to those below the median. More recently, a sophisticated
analytic approach indicated higher odds of ARV uptake and adherence as well as virologic
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suppression associated with antidepressant treatment in a longitudinal cohort.38 This work
supports earlier observational reports showing an association between appropriate
psychiatric treatment, improved ARV adherence, and improved HIV clinical outcomes
relative to patients with untreated mental illness.39,40
Experimental evidence on whether depression treatment improves clinical outcomes for
other chronic diseases
Several randomized controlled trials have been conducted to determine whether chronic
medical condition outcomes in patients with comorbid depression can be improved by
collaborative care models that integrate treatment for depression and the medical condition.
An RCT in patients with diabetes and depression41 reported improvements in depression but
no difference in the primary biomarker of diabetes control (HbA1c). A comparable
collaborative care model for hypertensive patients42 showed significantly improved
antihypertensive medication adherence as well as improved blood pressure in the group
randomized to the collaborative care intervention compared to the group randomized to
usual care. A larger RCT that enrolled patients with either poorly managed hypertension or
diabetes and comorbid depression, and proactively followed patients to provide support for
medication adherence, demonstrated improvements in a single combined endpoint of
hemoglobin A1c, cholesterol, systolic blood pressure, and depression scores in the
collaborative care arm relative to usual care.43 An RCT published in 2011 (after the start of
the current study) of a collaborative care model for HIV patients with depression in Veterans
Affairs (VA) treatment centers found significant reductions in HIV symptom severity but
did not find significant improvements in ARV adherence, using a self-reported measure of
ARV adherence and an adherence threshold of 95%.44 Of note, adherence in this study was
measured via self-report, and mean ARV adherence at baseline was relatively high (>90% in
both arms), potentially imposing a ceiling effect. This is the first published study the authors
are aware of that used a randomized design to test whether a collaborative depression and
HIV treatment model could improve ARV adherence. Whether different results would be
observed in non-VA patient populations, in populations with lower baseline adherence, or
using an objective measure of adherence remains undetermined.
Feasible model for integrating vigorous antidepressant prescription support into non-
psychiatric clinical settings
While improving the identification and management of depressive illness in PLWHA in
HIV clinics has promise to improve both HIV and depression outcomes, depression
treatment strategies need to be effective and sustainable in busy, real-world clinic settings.
The large-scale adaptation of psychotherapeutic interventions into HIV clinical care remains
challenging because of staffing requirements, resource constraints, and limited available
mental health treatment. Interventions that equip existing clinic staff with simple tools to
effectively prescribe and monitor antidepressant treatment may be implemented more
readily and scaled up more quickly into widespread practice.
A feasible depression intervention referred to as Measurement-Based Care (MBC) has been
successfully implemented in primary care medical settings for patients with comorbid
medical conditions.45,46 The MBC approach is based upon use of a clinically supervised
care manager to provide evidence-based antidepressant treatment recommendations to a
non-psychiatric prescribing provider, with care guided by systematic and ongoing measures
of depressive symptoms and side effects. Such a model allows care of the depressed HIV
patient to remain in the HIV clinic “medical home.” The foundation for MBC was
developed in the Texas Medication Algorithm Project (TMAP) in 199647 and was further
refined and extended for use in primary care medical settings in the design and
implementation of the Sequenced Treatment Alternatives to Relieve Depression (STAR*D)
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study, the largest prospective trial of depression treatment ever conducted.48,49 Using MBC,
STAR*D achieved equivalent rates of depression remission in both psychiatric and primary
care settings, demonstrating the strategy’s potential to deliver high-quality depression
management in non-psychiatric settings.46
Summary
Depression is prevalent in PLWHA. Observational data support an association between
depression and poor ARV adherence and HIV clinical outcomes. Standard depression
treatment approaches are efficacious in HIV-infected patients, and observational evidence
supports an association between depression treatment and improved ARV adherence. A
handful of small RCTs have tended to show improved ARV adherence among PLWHA
randomized to psychotherapy-based mental health treatment interventions. Interventions
focused on antidepressant treatment integrated into the HIV medical home, such as the MBC
model proposed in this project, will more likely be able to address the resource constraints
and lack of psychiatric treatment expertise that defines most HIV clinical settings and the
lack of access to mental health services that is the norm for most of the increasingly poor,
uninsured, and disenfranchised HIV population in the US. Antidepressant-based treatment
approaches have shown promise in improving medical outcomes for patients with
hypertension and diabetes, but at the time this study was designed, no similar studies had
been reported for HIV patients with depression.
Purpose
To address this gap in the literature, we designed and are implementing the SLAM DUNC
Study to test whether, relative to enhanced usual care, vigorous antidepressant management
supplemented with brief adherence counseling improves HIV medication adherence for
patients with HIV and depression. SLAM DUNC, or Strategies to Link Antidepressant and
Antiretroviral Management at Duke, UAB, and UNC, is a real-world, effectiveness-oriented,
three-site randomized controlled trial. In the intervention arm, antidepressant management is
provided by the treating HIV clinician with decision and follow-up support from a
Depression Care Manager (DCM), following the Measurement-Based Care (MBC) model
described below. In the intervention arm, the DCM also offers three motivational
interviewing-based adherence counseling sessions. In the enhanced usual care arm, the HIV
clinician receives the results of the participant’s baseline psychiatric evaluation and is free to
provide depression care or refer to another clinician for treatment, but does not receive
decision and follow-up support from the DCM.
Funding and registry
SLAM DUNC is a five-year study funded in 2009 by the National Institute of Mental Health
and the National Institute of Nursing Research (R01-MH086362) and is registered in
ClinicalTrials.gov (NCT01372605).
Design
SLAM DUNC is a three-site randomized controlled effectiveness trial. The implementation
sites are the infectious diseases clinics at three academic medical centers: Duke University
(lead site; Clinic 2J), the University of North Carolina at Chapel Hill (UNC Infectious
Diseases Clinic), and the University of Alabama at Birmingham (1917 Clinic).
The study design is based on a conceptual model that posits that HIV-infected patients with
depression will show improved ARV adherence following depression treatment and a
reduction in depressive severity. The reduction in depressive severity will in turn improve
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HIV medical care-related self-efficacy and coping behaviors (mediators; see Figure 1).
Adherence counseling will improve self-efficacy and coping, thereby improving adherence,
but without affecting depressive severity. The model posits that potential moderators of
intervention effectiveness include baseline depressive severity and comorbid substance
abuse and anxiety disorders, specifically, that higher baseline depressive severity and
comorbid disorders may be associated with reduced effectiveness.
Inclusion and exclusion criteria
Patients seeking HIV care at participating sites are eligible if they are HIV-positive, ages
18–65 years old, English-speaking, are currently prescribed any FDA-approved
antiretroviral medication or expect to start ART within the next month, have a total score of
10 or higher on the Patient Health Questionnaire-9, and are subsequently confirmed to have
a current major depressive episode on the Mini International Neuropsychiatric Interview
(MINI).50 Both new and established patients are eligible for enrollment. Patients are
excluded if they have a history of or current bipolar or psychotic disorder, have failed
adequate trials of two or more different antidepressants in the current major depressive
episode, have current substance dependence requiring inpatient hospitalization, demonstrate
acute suicidality or other psychiatric presentation requiring immediate hospitalization, or are
not mentally competent. Age range and psychiatric comorbidity exclusion criteria reflect the
fact that different depression treatment approaches are indicated for adolescents, those over
65, or for depressive symptoms presenting as part of a bipolar or psychotic disorder. Patients
with treatment-resistant depression are unlikely to respond to the antidepressant
management strategy used in this study, so patients are excluded who have failed adequate
trials of two or more FDA-approved antidepressant medications in the current major
depressive episode. For the purposes of this study, to be considered an adequate trial of an
antidepressant, the patient must have been taking a moderate to high dose (generally, at least
half the maximum FDA-approved dose) for at least six weeks. Patients are not excluded if
they are on an antidepressant at enrollment, as long as they do not meet the threshold of
having failed two or more adequate antidepressant trials. Patients are not excluded if they
are involved in other substance use or mental health counseling treatment.
Pregnancy
Pregnant women are not categorically excluded from the study, given the greater potential
benefits to mother and child of improved adherence and mental health and the relatively safe
profile of antidepressants in pregnancy and postpartum.51–53 The American College of
Obstetrics and Gynecology currently recommends that treatment with SSRIs or selective
norepinephrine reuptake inhibitors (SNRIs) during pregnancy should be individualized.54
The HIV provider and patient make joint decisions about testing for pregnancy and
antidepressant prescription for pregnant or breastfeeding women as part of usual clinical
care in both conditions. The research study does not provide pregnancy testing but
encourages female participants, if they know or suspect they may be pregnant, to discuss the
issue with their provider as part treatment planning. The provider will help them weigh
potential neonatal effects against the benefits to both mother and child of successfully
treating a major depressive disorder.
Enrollment
After provision of informed consent, psychiatric inclusion and exclusion criteria are
assessed with the Mini International Neuropsychiatric Interview (MINI).50 After
confirmation of eligibility, baseline research data collection is completed by a blinded study
team member. Upon completion of baseline data collection, the participant is randomized.
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In the intervention condition, patients receive ongoing depression monitoring and HIV
providers receive initial and ongoing antidepressant management decision support from the
Depression Care Manager (DCM) following the Measurement-Based Care (MBC) model,
described in more detail below. In brief, MBC is designed to equip clinically supervised
non-psychiatric providers (DCMs) to work with prescribing providers to provide vigorous
antidepressant management and achieve maximal depression response. The DCM performs
frequent, standardized monitoring of side effects and depressive symptoms, and uses an
algorithm to provide decision support that focuses on responding promptly to distressing
side effects and increasing doses as needed to achieve full depression remission. In the
intervention condition, patients additionally receive three motivational interviewing-based
counseling sessions focused on antiretroviral medication adherence, adapted from an
adherence intervention (PACT).55
In the enhanced usual care arm, HIV providers receive the results of the initial psychiatric
assessment (e.g., confirmation of diagnosis of an episode of major depressive disorder) but
do not receive further decision support or patient follow-up from the DCM. The HIV
provider is free to implement any depression treatment plan he or she wishes, including
initiating an antidepressant or referring to other resources. A paper version of the decision
algorithm guiding the intervention arm is available in the common workspace of all clinics
and is accessible to providers of patients in the enhanced usual care arm.
Outcomes
The study’s primary outcome is a comparison between the arms of ARV adherence at 6
months, measured by unannounced phone-based pill count.56 Secondary outcomes include
antiretroviral medication adherence at 12 months; viral load at 6 and 12 months; depressive
symptomatology at 6 and 12 months, measured by the Hamilton Rating Scale for
Depression; HIV medical appointment adherence over 12 months; and cost-effectiveness,
measured by changes in cost of prescriptions and health care utilization relative to the cost
of the intervention.
Schedule of events
Figure 2 describes the flow of study activities, and Figure 3 summarizes the schedule of
research and clinical activities from a participant’s perspective.
Design choices and consideration of strengths and limitations
SLAM DUNC is designed as an effectiveness trial, with the primary goal of measuring the
impact of real-world implementation of vigorous antidepressant management on HIV
medication adherence. This principle led to several design choices which distinguish the
design from an efficacy study design:
1. The study does not provide or pay for recommended antidepressant medications.
Barriers or delays in accessing antidepressant medications are systematically
measured.
2. The study does not require that providers follow the Depression Care Manager’s
antidepressant dosing recommendations. Reasons for provider divergence from
recommendations are systematically measured.
3. The study’s inclusion criteria are as broad as possible. Specifically, participation is
not restricted to patients with depression alone, but is open to patients with
comorbid substance abuse and anxiety disorders (including those receiving
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substance abuse treatment), in recognition of the fact that the majority of HIV
patient with depression have at least one other Axis I disorder as well.57
We decided to focus this study on estimating the impact of MBC as a clinic-wide
intervention. This design choice led to three key decisions:
1. Since MBC in a real-world context would likely be offered to all depressed
patients, not just to those with low HIV medication adherence, we decided to enroll
all patients with depression regardless of initial HIV medication adherence.
2. Since our goal was to estimate the “value added” of MBC relative to current
depression management practice, and since it would be unethical to prohibit
depressed patients from receiving depression treatment, we did not set any bounds
around the treatment plans that providers and patients could pursue in the enhanced
usual care arm.
3. As the question of interest was to estimate the effect of the presence vs. absence of
MBC, we selected a usual care comparison arm rather than an attention-matched
comparison arm, since the latter would not represent the state of care in the absence
of MBC.
Much discussion at the design stage focused on blinding and its impact on the comparison
condition. The nature of the intervention makes blinding unfeasible for participants,
providers, and study interventionists (although research outcome assessors are blinded to
study condition). The absence of blinding raises the question of whether participants’
knowledge of treatment assignment could bias results. It is important to note that this study
is not a trial of a specific medication, but of a care coordination strategy, and that
participants in both arms are in fact eligible to receive antidepressants or other depression
treatment. The key element that differs between the arms is whether or not the Depression
Care Manager collaborates with the HIV provider in developing a treatment plan and
providing follow-up. In order to avoid giving participants the impression that one arm is
denied treatment, the consent form states that in one arm, the Depression Care Manager will
work with the HIV provider to develop a depression treatment plan, while in the other arm,
the HIV provider will develop a depression treatment plan on his or her own.
Intervention condition: Measurement-Based Care and motivational
interviewing-based adherence counseling
Overview of MBC
Measurement-Based Care (MBC) is a state-of-the-art depression care management strategy
that trains clinic support personnel as Depression Care Managers (DCMs) who assist non-
psychiatric clinicians in providing guideline-concordant, vigorous antidepressant treatment.
Functioning as decision support for the clinicians, these DCMs perform initial assessments,
monitor symptoms and side effects, and make dosing recommendations to the treating
clinician (here, the HIV medical provider). DCMs guide providers in choosing from a list of
antidepressants that have been assessed for efficacy, tolerability, and interaction with ARV
medications.
DCMs receive initial training in the MBC algorithm and antidepressant dosing, side effects,
and interactions with antiretroviral medications. A psychiatric professional provides weekly
clinical supervision and as-needed support to the DCM to ensure quality of care and provide
ongoing training.
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In the SLAM DUNC Study, depressive symptom severity is assessed with the Patient Health
Questionnaire-9 (PHQ-9). The PHQ-9 score can range from 0–27, with 0–4 indicating no
depression, 5–9 indicating mild depressive symptoms, 10–19 indicating moderate depressive
symptoms, and 20–27 indicating severe depressive symptoms. A score of 10 or above is
normally used as a cutoff indicating likely major depression, including in HIV patients.58
Antidepressant side effect burden is assessed with the Frequency, Intensity, and Burden of
Side Effects Rating (FIBSER).59
Schedule of events
At baseline, the DCM measures depressive severity. If the patient is currently on an
antidepressant, the DCM also measures the baseline antidepressant side effect burden. The
DCM then recommends a treatment plan to the HIV clinician.
Critical Decision Points (CDP) for possible antidepressant medication changes occur every 4
weeks. At these visits, the DCM re-assesses depressive symptoms and side effects. Based on
the depressive symptoms and side effects, the DCM makes a new treatment recommendation
to the HIV clinician guided by the decision algorithm. In general, if the side effects are
intolerable, the recommendation is to address the side effects if possible, reduce the dose of
the antidepressant, or switch to a new antidepressant. If side effects are absent or tolerable,
the recommendation is generally to maintain the dose if the patient has achieved remission
or increase the dose if remission has not been achieved.
The DCM has interim contacts with the patient every two weeks between Critical Decision
Points. These are brief contacts to assess side effects. Generally no treatment change
recommendation arises from these contacts unless distressing side effects are noted.
At CDP 3 (after 12 weeks on a given antidepressant regimen), if the patient has achieved
remission, the recommendation is to continue on the same dose and enter a maintenance
phase of treatment, during which the patient and DCM have contact every 2–3 months to
confirm continued remission. If the patient has not achieved remission, the recommendation
is generally to declare the treatment a failure and recommend augmentation with a second
antidepressant or switch to a new antidepressant. After two failed trials the recommendation
is to refer for a psychiatric consultation.
The treatment team
Treatment decisions are the result of collaboration between the patient, HIV clinician, DCM,
and supervising psychiatrist (Figure 3). The depression care manager completes
standardized assessments with the patient and follows the MBC algorithm to provide
recommendations to the HIV clinician as described above. The HIV clinician and patient
make final treatment decisions with decision support from the DCM. The supervising
psychiatrist reviews all encounters, recommendations, and treatment plans with the DCM on
a weekly basis to provide quality assurance and ongoing training, monitor adherence to the
MBC algorithm, and offer any supplemental recommendations. This weekly supervision is
facilitated by a web-based patient tracking system in which key data for each encounter
(depressive severity, side effects, algorithm recommendation, treatment plan, psychiatrist’s
review) are organized for easy review. The supervising psychiatrist is also available to the
DCM and HIV clinician for consultations about individual patients as needed.
Adherence counseling
Intervention arm participants have three counseling sessions with the DCM focused on
antiretroviral medication adherence, based on a theoretically grounded, Motivational
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Interviewing approach manualized in the Participating And Communicating Together
(PACT) intervention.55,60 Motivational interviewing is a client-centered, goal-directed
counseling style originally developed to treat substance abuse and later adapted to facilitate
a broader spectrum of health behavior changes.61–63 Motivational interviewing does not
follow an invariant structure but includes five counseling techniques aimed at helping clients
resolve ambivalence about a health behavior: (1) expressing empathy; (2) developing
discrepancy; (3) avoiding argument; (4) rolling with resistance; and (5) supporting self-
efficacy.61 Motivational interviewing is based on the premise that a patient’s readiness for
behavior change is not a fixed characteristic of the person, but a fluctuating factor that can
be altered as a result of an interaction with a counselor.64 In SLAM DUNC, participants
have three one-hour sessions (one in-person and two by phone) over three months. DCMs
capture the content of these sessions on standardized data recording sheets and have regular
supervision with a Motivational Interviewing supervisor to ensure fidelity.
Research Procedures
Unannounced phone-based pill counts
The primary outcome measure of ARV adherence is measured through unannounced phone-
based pill counts. Unannounced home-based pill counts were established as an objective and
valid measure of ARV adherence by Bangsberg and colleagues,65 and the methodology was
adapted for phone implementation and validated by Kalichman and colleagues.56 A research
assessor blinded to study arm contacts each participant at approximately 30-day intervals for
12 months to count the participant’s current antiretrovirals and to gather information on pills
dispensed, pills discarded, and other gains and losses since the last pill count. The study
provides cell phones when needed to assist in reaching participants.
Research interviews
Information on additional outcomes (depressive severity, health care utilization, sexual risk
behaviors), covariates (sociodemographics), and potential mediators and moderators of
intervention effects (self-efficacy, coping behaviors, comorbid mental health diagnoses) are
captured during research interviews conducted every three months by a research assessor
blinded to study arm.
Sample size and power
In determining sample size requirements, the study team focused on the definition of a
minimum clinically significant difference in the primary outcome, continuously measured
ART adherence. The team defined this difference as a change of ≥10 percentage points; a
study result showing a change <10 percentage points was believed to be unlikely to
substantially influence policy or practice. Based on standard deviation estimates published
in similar studies,34 a 5% Type I error probability, two-tailed tests, and 80% retention at the
primary endpoint, the target sample was calculated to have 80–90% power to detect a
difference of ≥10 percentage points.
Monitoring of serious adverse events
The occurrence of serious adverse events is assessed, reported, and monitored systematically
and carefully. The serious adverse event of primary concern in this population is suicide.
Suicidal ideation is probed at baseline for all participants, at every quarterly research
interview for all participants, and at every MBC contact for intervention participants. It was
expected that the prevalence of any level of suicidal ideation would be high: approximately
50% of patients with depression in medical or psychiatric settings endorse some level of
suicidal ideation.66,67 In SLAM DUNC, if suicidal ideation is reported, it is classified by the
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assessor as either passive (thoughts of death without a specific plan of self-harm), active not
requiring immediate intervention (a specific plan of self-harm without immediate intent), or
active requiring immediate intervention (a specific plan of self-harm with immediate intent).
When a participant reports active suicidal ideation that requires immediate intervention, the
study staff member speaking with the patient immediately contacts a clinician, if in clinic by
following the clinic’s suicidality response protocol, or if not in clinic by paging a study
psychiatrist. All reports of suicidal ideation are logged either on the clinical supervision
website (MBC encounters) or through an SAE reporting system (research interviews) and
are reviewed by a study psychiatrist. Other SAEs (hospitalizations, emergency department
visits) are logged in similar fashion. Overall frequency of suicidal ideation and other SAEs
in the study population is reviewed quarterly by the entire investigative team to assess
whether prevalence is exceeding expectations. An independent Data Safety and Monitoring
Board reviews SAEs annually.
Human Subjects Protection and Ethical Approvals
This protocol has been approved by the Duke University Medical Center Institutional
Review Board (IRB) (#Pro00019233), the University of North Carolina at Chapel Hill
Biomedical IRB (#09-1882), and the University of Alabama at Birmingham IRB
(#F110202004). Human subjects protection issues of particular consideration during the
approval process included careful monitoring of suicidal ideation as well as procedures for
situations in which a concern of an imminent threat of harm to or by the participant might
require a breach to confidentiality.
Current status
SLAM DUNC began enrollment in April 2010 with target enrollment of 390. As of
December 2011, 153 participants had been enrolled and randomized. Enrollment is projected
to continue through April 2013 with follow-up through April 2014.
Conclusion
SLAM DUNC uses a randomized clinical effectiveness trial design to test whether a
depression treatment model integrated into routine HIV clinical care affects ARV adherence
and improves HIV clinical outcomes relative to a usual care control. Key components of the
intervention include use of depression care managers (DCMs) to provide treatment
recommendations guided by an evidence-based Measurement-Based Care algorithm; weekly
supervision of DCMs through a review of enrolled patients by a psychiatric care team;
delivery of recommendations to the HIV clinicians by the DCMs; monthly patient visits at
critical decision points to assess the need for a modification of the antidepressant
management plan; and vigorous dose escalation during the acute phase of antidepressant
treatment. Key components of the study design include estimation of effectiveness in real-
world settings, the use of unannounced phone-based pill counts as the measure of the
primary outcome variable, ARV adherence, and a primary focus on the effect of depression
treatment on HIV-related outcomes including ARV adherence.
A strength of this study is the use of an algorithm and model–Measurement-Based Care–that
has been successfully applied in multiple busy medical clinic settings to improve depression
outcomes in patients with comorbid medical illnesses. Since the DCM role can be
effectively filled by a behavioral health provider, nurse, or care manager given appropriate
training and supervision, and the intervention has limited time requirements, this model is
potentially replicable in a wide range of resource-constrained treatment settings for HIV or
other chronic medical illnesses. Given the high prevalence of depression in HIV patients and
the increasing push to coordinate multiple medical services in one “medical home,”68 the
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model deployed in this study is likely to be applicable for a substantial proportion of HIV
patients, especially in settings with limited access to specialized mental health services.
Important outcomes of this study will be evidence of the effectiveness of MBC in treating
depression in PLWHA, evidence of the effectiveness of MBC in improving HIV-related
outcomes, a detailed analysis of process measures contributing to or hindering its
implementation in our sites, and a treatment manual to facilitate replication.
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Flowchart of study activities.
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Schedule of study activities from a participant’s perspective.
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Communication flow in Measurement-Based Care treatment team.
DCM conducts standardized assessment & monitoring of patient’s depression. DCM
provides decision support to HIV clinician about depression treatment plan. HIV clinician
decides on treatment plan with patient. Psychiatrist provides weekly and as-needed
supervision to DCM. Psychiatrist available for consultation on complicated cases.
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